GlassScriptPhysician profile
Bellamy C Brook
NPI 1477511749
$1,565.44
in general payments reported to CMS, 2019-2025
18 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.78 · 2021: $156 · 2022: $126 · 2023: $312 · 2024: $374 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.75 | 2021-2025 | |
| Abbvie INC. | $170.88 | 2021-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $160.18 | 2023-2025 | Farxiga, Breztri |
| Amgen INC. | $159.18 | 2021-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.74 | 2025 | Caplyta |
| Lilly USA, LLC | $133.10 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $110.10 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $98.22 | 2023-2025 | Dupixent |
| Genzyme Corporation | $68.07 | 2024-2025 | |
| Corcept Therapeutics | $39.91 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $38.30 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $34.98 | 2022-2023 | |
| Philips North America LLC | $24.02 | 2024 | (Ck7) Extended Holter |
| Boston Scientific Corporation | $23.63 | 2023 | |
| Allergan, INC. | $19.78 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.95 | 2022 | |
| Alk-Abello, INC | $18.03 | 2023 | Grastek, Ragwitek, Odactra |
| Glaxosmithkline, LLC. | $14.62 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bellamy Brook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.